Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients

Table 1

Socio-demographic characteristics of study population (𝑛=350).

Variables	Type of Statin
	Atorvastatin; (𝑛=150); 𝑛 (%)	Rosuvastatin; (𝑛=100); 𝑛 (%)	Pravastatin; (𝑛=100); 𝑛 (%)
Age (Mean ± SD)	57.4±12.7	55.8±9.8	57.5±10.3
Age group
<65 years	117 (78.0)	80 (80.0)	76 (76.0)
≥65 years	33 (22.0)	20 (20.0)	24 (24.0)
Nationality
Qatari	110 (73.3)	69 (69.0)	79 (79.0)
Non-Qatari	40 (26.7)	31 (31.0)	21 (21.0)
Gender
Male	54 (36.0)	55 (55.0)	34 (34.0)
Female	96 (64.0)	45 (45.0)	66 (66.0)
BMI (Mean ± SD)	33.6±8.3	31.9±6.4	33.3±7.1
BMI group
<25 kg/m^2	10 (6.7)	11 (11.0)	8 (8.0)
25–30 kg/m^2	40 (26.7)	36 (36.0)	23 (23.0)
≥30 kg/m^2	100 (66.7)	53 (53.0)	69 (69.0)
Smokers
Yes	19 (12.7)	17 (17.0)	12 (12.0)
No	131 (87.3)	83 (83.0)	88 (88.0)
Alcohol consumer
Yes	2 (1.3)	1 (1.0)	5 (5.0)
No	148 (98.7)	99 (99.0)	95 (95.0)
HTN
Yes	130 (86.7)	95 (95.0)	94 (94.0)
No	20 (13.3)	5 (5.0)	6 (6.0)
DM
Type I	6 (4.0)	7 (7.0)	—
Type II	144 (96.0)	93 (93.0)	100 (100)
DM duration
<5 years	17 (11.3)	18 (18.0)	9 (9.0)
5–10 years	47 (31.3)	35 (35.0)	35 (35.0)
>10 years	86 (57.3)	47 (47.0)	56 (56.0)

∗Continuous variables are presented as mean ± SD and categorical variables as numbers (percentages).